Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

DG DISPATCH - ICACT: Anastrozole May Replace Tamoxifen In Postmenopausal Breast Cancer By Jill Stein Special to DG News PARIS, FRANCE -- February 1, 2000 -- New data support the use of anastrozole as an alternative to tamoxifen for the treatment of postmenopausal women with advanced breast cancer. The findings were presented at the 10th International Congress on Anti-Cancer Treatment (ICACT) and are based on the preliminary results of two similarly designed clinical trials in which postmenopausal women with advanced breast cancer were randomized to receive anastrozole, 1 mg once daily, or tamoxifen, 20 mg once daily. All patients were eligible for hormone therapy. That is, they were estrogen receptor positive and/or progesterone receptor positive or their tumor receptor status was unknown. Patients who were included may have received prior adjuvant hormonal therapy or chemotherapy. A drug-free period of 12 months was required for those patients who received adjuvant tamoxifen. Professor Jacques Bonneterre, with the Centre Oscar Lambret, in Lille, France, reported the results of a study in which 668 patients were randomized and followed for a median of 19 months. The trial was conducted in Europe and the rest of the world (except for Canada and the US). Disease progression was observed in 73 percent of anastrozole-treated patients and 75 percent of tamoxifen-treated patients. The median time to disease progression was eight months for both groups, and the overall response rate was 32 percent in both groups. Clinical benefit rates (a sum of the complete remission, partial remission, and stable disease rates at 24 weeks) were 56 percent in the anastrozole group and 55 percent in the tamoxifen group. In the second study, 353 women were randomized at treatment sites in the US and Canada and followed for a median of 18 months. Disease progression was observed in 67 percent of anastrozole-treated patients and 76 percent of tamoxifen-treated patients. The median time to disease progression was 11 months in the anastrozole and 5.6 months in the tamoxifen cohort. The overall response was 20 percent and 17 percent and the rates of clinical benefit were 58 percent and 45 percent for the two groups, respectively. Both treatment arms in both trials were generally well tolerated. Related Links: tamoxifen (Tamoxifen) and anastrozole (Arimidex). E-mail this page to a friend or colleague! To print, use this version